2020

In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell…

LUMICKS is pleased to announce a collaboration agreement with clinical-stage biotech company Leucid Bio, which seeks to utilize LUMICKS’ z-Movi® Cell Avidity Analyzer to accelerate entry of immunotherapeutic candidates into clinical trials. The goal of the partnership is to evaluate the efficacy of Leucid Bio’s next-generation CAR T-cells using the…

In a move to broadly unlock Dynamic Single-Molecule (DSM) analysis, LUMICKS simultaneously launched two major initiatives: a new business line for reagents, biochemistry kits, and services, as well as its Harbor platform for sharing of DSM scripts. These new resources dramatically simplify the experimental workflow and make DSM analysis accessible…

LUMICKS is proud to announce the opening of its branch office in Beijing, China. As LUMICKS continues to expand within the rapidly developing life sciences and immuno-oncology market in the Asia Pacific Region (APR), the new office will allow to better serve the market opportunity, support local customers, and collaborate…

We are excited to announce that LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population…